Siemens Healthineers released its third fiscal quarter report ending June 30, 2024 on July 31, 2024 in Erlangen, Germany.

Q3 of fiscal year 2024.

• The equipment order delivery ratio was good, reaching 1.07, which further increased the already high order volume.
• Despite the continuing delay of orders from China, the overall performance of the company showed excellent performance compared to the same period last year (excluding the COVID-19 antigen rapid testing business, comparable revenue increased by 10.1%), and comparable revenue growth was 4.3%.
• Compared with the strong performance of the same period last year, the comparable revenue of the imaging diagnosis business increased by 3.8%, and the adjusted pre-tax profit margin was 20.0%.
• The comparable revenue of the in vitro diagnosis business increased by 2.1%; the adjusted pre-tax profit margin was 7.4%, significantly higher than the same period last year.
• Varian's comparable revenue increased by 9.6%; the adjusted pre-tax profit margin significantly increased compared to the same period last year to 16.6%.
• Compared with the strong performance of the same period last year, the comparable revenue of the clinical treatment business increased by 0.4%; the adjusted pre-tax profit margin was 13.9%.
• The overall adjusted pre-tax profit margin reached 15.2%.
• Adjusted basic earnings per share is 0.52 euros.

Outlook for fiscal year 2024.

We confirm that Siemens Healthineers' comparable revenue for fiscal year 2024 is expected to increase by 4.5% to 6.5%. Excluding revenue from the COVID-19 antigen rapid testing business, the comparable revenue growth rate is expected to be between 5.0% and 7.0%. Adjusted basic earnings per share are expected to reach between 2.10 euros and 2.30 euros.

Bernd Montag, CEO of Siemens Healthineers: 'Although Chinese orders continue to be delayed, we have made good overall progress in the third quarter, especially in the strong performance of Varian and the in vitro diagnosis business. Based on this, we confirm our performance expectations for this fiscal year.'

About Siemens Healthineers

Innovate for a healthier world. Siemens Healthineers is a global leading medical equipment, solutions and services provider, operating in more than 180 countries and regions and directly conducting business in more than 70 countries and regions. Siemens Healthineers consists of Siemens Healthineers AG (Frankfurt Securities Exchange Code: SHL) and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to high-quality medical resources while conquering deadly diseases that threaten human health. Siemens Healthineers' business covers medical imaging, in vitro diagnosis, cancer treatment and minimally invasive treatment, and strengthens the strength of each business through digital technology and artificial intelligence. As of the fiscal year 2023 (September 30, 2023), Siemens Healthineers has approximately 71,000 employees worldwide, with revenue of approximately 21.7 billion euros. For more information, please visit